Antibody to a Synthetic Oligopeptide in Subjects at Risk for Human Immunodeficiency Virus Infection

Overview

Journal J Clin Microbiol

Specialty Microbiology

Date 1987 Aug 1

PMID 3476491

Citations 26

Authors

R S Smith

R B Naso

J Rosen

A Whalley

Y L Hom

K Hoey

C J Kennedy

J A McCutchan

S A Spector

D D Richman

Affiliations

Soon will be listed here.

Abstract

Detection of antibodies to human immunodeficiency virus (HIV) by enzyme-linked immunosorbent assay (ELISA) is the accepted method to screen blood products at risk to transmit infection. The presence of antibodies to HIV in 565 serum specimens from 274 patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex, symptomatic and asymptomatic subjects at risk for AIDS, and controls was determined with an ELISA that incorporates synthetic peptides (designated E32/E34) representing sequences in the envelope glycoprotein gp41. Of 105 specimens from patients with AIDS or AIDS-related complex, 3 specimens that were negative by commercially licensed ELISA and immunoblot test were similarly unreactive in the E32/E34 ELISA. For homosexual men with generalized lymphadenopathy, 186 specimens were positive by the E32/E34 ELISA and 63 specimens were negative. In comparison, with the licensed ELISA, 184 of these samples were positive and 65 samples were negative. The two samples that were positive in the E32/E34 ELISA but not the commercial kit were also positive by immunoblotting. Sequential sera from one individual who apparently underwent seroconversion according to the commercial assays were all positive by E32/E34 ELISA and immunoblotting. Thus, the ELISA with synthetic peptides is an extremely sensitive and specific test of antibody response to HIV and has not yet yielded a negative result with a Western blot (immunoblot)-confirmed antibody-positive serum.

Citing Articles

Linear epitopes of the replication-activator protein of Epstein-Barr virus recognised by specific serum IgG in nasopharyngeal carcinoma.

Cheng H, Foong Y, AbuSamah A, Dillner J, Sam C, Prasad U Cancer Immunol Immunother. 1995; 40(4):251-6.

PMID: 7750123 PMC: 11037714. DOI: 10.1007/BF01519899.

Identification of group-common linear epitopes in structural and nonstructural proteins of enteroviruses by using synthetic peptides.

Cello J, Samuelson A, Stalhandske P, Svennerholm B, Jeansson S, Forsgren M J Clin Microbiol. 1993; 31(4):911-6.

PMID: 7681848 PMC: 263586. DOI: 10.1128/jcm.31.4.911-916.1993.

Specificity of antibodies produced against native or desialylated human immunodeficiency virus type 1 recombinant gp160.

Benjouad A, Gluckman J, Montagnier L, Bahraoui E J Virol. 1993; 67(3):1693-7.

PMID: 7679751 PMC: 237545. DOI: 10.1128/JVI.67.3.1693-1697.1993.

Synthetic peptides representing sequences within gp41 of HIV as immunogens for murine T- and B-cell responses.

Brown L, WHITE D, Agius C, Kemp B, Yatzakis N, Poumbourios P Arch Virol. 1995; 140(4):635-54.

PMID: 7540829 DOI: 10.1007/BF01309955.

B- and T-lymphocyte responses to an immunodominant epitope of human immunodeficiency virus.

Schrier R, Gnann Jr J, Langlois A, Shriver K, Nelson J, Oldstone M J Virol. 1988; 62(8):2531-6.

PMID: 3260630 PMC: 253681. DOI: 10.1128/JVI.62.8.2531-2536.1988.

References

Symington J, Green M, Brackmann K . Immunoautoradiographic detection of proteins after electrophoretic transfer from gels to diazo-paper: analysis of adenovirus encoded proteins. Proc Natl Acad Sci U S A. 1981; 78(1):177-81. PMC: 319014. DOI: 10.1073/pnas.78.1.177. View

Barre-Sinoussi F, Chermann J, Rey F, Nugeyre M, Chamaret S, Gruest J . Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983; 220(4599):868-71. DOI: 10.1126/science.6189183. View

Saxinger C, Gallo R . Methods in laboratory investigation. Application of the indirect enzyme-linked immunosorbent assay microtest to the detection and surveillance of human t cell leukemia-lymphoma virus. Lab Invest. 1983; 49(3):371-7. View

Popovic M, Sarngadharan M, Read E, Gallo R . Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science. 1984; 224(4648):497-500. DOI: 10.1126/science.6200935. View

Schupbach J, Popovic M, Gilden R, Gonda M, Sarngadharan M, Gallo R . Serological analysis of a subgroup of human T-lymphotropic retroviruses (HTLV-III) associated with AIDS. Science. 1984; 224(4648):503-5. DOI: 10.1126/science.6200937. View

Sarngadharan M, Popovic M, Bruch L, Schupbach J, Gallo R . Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS. Science. 1984; 224(4648):506-8. DOI: 10.1126/science.6324345. View

Lerner R . Antibodies of predetermined specificity in biology and medicine. Adv Immunol. 1984; 36:1-44. DOI: 10.1016/s0065-2776(08)60898-6. View

GOLDSMITH M . HTLV-III testing of donor blood imminent; complex issues remain. JAMA. 1985; 253(2):173-5, 179-81. DOI: 10.1001/jama.253.2.173. View

Weiss S, Goedert J, Sarngadharan M, Bodner A, Gallo R, Blattner W . Screening test for HTLV-III (AIDS agent) antibodies. Specificity, sensitivity, and applications. JAMA. 1985; 253(2):221-5. View

10.

Salahuddin S, Groopman J, Markham P, Sarngadharan M, Redfield R, McLane M . HTLV-III in symptom-free seronegative persons. Lancet. 1984; 2(8417-8418):1418-20. DOI: 10.1016/s0140-6736(84)91619-2. View

11.

Schupbach J, Haller O, Vogt M, Luthy R, Joller H, Oelz O . Antibodies to HTLV-III in Swiss patients with AIDS and pre-AIDS and in groups at risk for AIDS. N Engl J Med. 1985; 312(5):265-70. DOI: 10.1056/NEJM198501313120502. View

12.

Landesman S, Ginzburg H, Weiss S . The AIDS epidemic. N Engl J Med. 1985; 312(8):521-5. DOI: 10.1056/nejm198502213120829. View

13.

Ratner L, Haseltine W, Patarca R, Livak K, Starcich B, Josephs S . Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature. 1985; 313(6000):277-84. DOI: 10.1038/313277a0. View

14.

Muesing M, Smith D, Cabradilla C, Benton C, Lasky L, Capon D . Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus. Nature. 1985; 313(6002):450-8. DOI: 10.1038/313450a0. View

15.

Shaw G, Broder S, Essex M, Gallo R . Human T-cell leukemia virus: its discovery and role in leukemogenesis and immunosuppression. Adv Intern Med. 1984; 30:1-27. View

16.

Osterholm M, Bowman R, Chopek M, McCULLOUGH J, Korlath J, Polesky H . Screening donated blood and plasma for HTLV-III antibody. Facing more than one crisis?. N Engl J Med. 1985; 312(18):1185-9. DOI: 10.1056/NEJM198505023121810. View

17.

Barin F, McLane M, Allan J, Lee T, Groopman J, Essex M . Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients. Science. 1985; 228(4703):1094-6. DOI: 10.1126/science.2986291. View

18.

Veronese F, Devico A, Copeland T, Oroszlan S, Gallo R, Sarngadharan M . Characterization of gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene. Science. 1985; 229(4720):1402-5. DOI: 10.1126/science.2994223. View

19.

Saag M, Britz J . Asymptomatic blood donor with a false positive HTLV-III Western blot. N Engl J Med. 1986; 314(2):118. DOI: 10.1056/nejm198601093140212. View

20.

Groopman J, Chen F, Hope J, Andrews J, SWIFT R, Benton C . Serological characterization of HTLV-III infection in AIDS and related disorders. J Infect Dis. 1986; 153(4):736-42. DOI: 10.1093/infdis/153.4.736. View